Parent, Guarantor, Non-Guarantor Unaudited Consolidating Condensed Financial Statements - Consolidated Condensed Statements of Cash Flows (Detail) - USD ($)
$ in Thousands |
3 Months Ended |
Mar. 31, 2016 |
Mar. 31, 2015 |
| Cash flows from operating activities: |
|
|
| Net income (loss) |
$ (95,835)
|
$ 3,778
|
| Adjustments to reconcile net income (loss) |
|
|
| Depreciation and amortization |
35,814
|
40,539
|
| Accretion Expense |
419
|
0
|
| (Gain) loss on disposition of assets |
60
|
(2,441)
|
| Deferred income tax expense (benefit) |
63,411
|
6,304
|
| Expenses not requiring cash |
(426)
|
1,737
|
| Equity in net earnings of subsidiaries |
0
|
0
|
| Accounts and notes receivable |
(381)
|
(6,650)
|
| Accrued income taxes |
(3,600)
|
2,614
|
| Other assets |
(304)
|
(20,087)
|
| Accounts payable and accrued liabilities |
(14,437)
|
54,045
|
| Net cash provided by (used in) operating activities |
(15,279)
|
67,231
|
| Cash flows from investing activities: |
|
|
| Capital expenditures |
(7,889)
|
(33,455)
|
| Proceeds from the sale of assets |
54
|
246
|
| Proceeds from insurance settlements |
0
|
2,500
|
| Net cash (used in) investing activities |
(7,835)
|
(30,709)
|
| Cash flows from financing activities: |
|
|
| Repayments of long-term debt |
|
(30,000)
|
| Paydown on term note |
0
|
(30,000)
|
| Payment of debt issuance costs |
0
|
(1,359)
|
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability |
(2,000)
|
0
|
| Excess tax benefit from stock-based compensation |
(753)
|
(420)
|
| Intercompany advances, net |
0
|
0
|
| Net cash (used in) financing activities |
(2,753)
|
(31,779)
|
| Net increase (decrease) in cash and cash equivalents |
(25,867)
|
4,743
|
| Cash and cash equivalents, beginning of year |
134,294
|
108,456
|
| Cash and cash equivalents, end of period |
108,427
|
113,199
|
| Parent [Member] |
|
|
| Cash flows from operating activities: |
|
|
| Net income (loss) |
(95,835)
|
3,222
|
| Adjustments to reconcile net income (loss) |
|
|
| Depreciation and amortization |
0
|
0
|
| Accretion Expense |
0
|
|
| (Gain) loss on disposition of assets |
0
|
0
|
| Deferred income tax expense (benefit) |
(57,677)
|
7,932
|
| Expenses not requiring cash |
1,740
|
2,443
|
| Equity in net earnings of subsidiaries |
16,225
|
(8,988)
|
| Accounts and notes receivable |
0
|
19
|
| Accrued income taxes |
10,680
|
(10,727)
|
| Other assets |
(37,191)
|
25,016
|
| Accounts payable and accrued liabilities |
(9,521)
|
(10,549)
|
| Net cash provided by (used in) operating activities |
(56,225)
|
(7,496)
|
| Cash flows from investing activities: |
|
|
| Capital expenditures |
0
|
0
|
| Proceeds from the sale of assets |
0
|
0
|
| Proceeds from insurance settlements |
|
0
|
| Net cash (used in) investing activities |
0
|
0
|
| Cash flows from financing activities: |
|
|
| Repayments of long-term debt |
|
(30,000)
|
| Payment of debt issuance costs |
|
(1,359)
|
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability |
0
|
|
| Excess tax benefit from stock-based compensation |
(753)
|
(420)
|
| Intercompany advances, net |
28,815
|
34,251
|
| Net cash (used in) financing activities |
28,062
|
2,472
|
| Net increase (decrease) in cash and cash equivalents |
(28,163)
|
(5,024)
|
| Cash and cash equivalents, beginning of year |
73,985
|
36,728
|
| Cash and cash equivalents, end of period |
45,822
|
31,704
|
| Guarantor [Member] |
|
|
| Cash flows from operating activities: |
|
|
| Net income (loss) |
(14,313)
|
2,319
|
| Adjustments to reconcile net income (loss) |
|
|
| Depreciation and amortization |
23,125
|
23,311
|
| Accretion Expense |
419
|
|
| (Gain) loss on disposition of assets |
56
|
(52)
|
| Deferred income tax expense (benefit) |
(5,185)
|
(3,117)
|
| Expenses not requiring cash |
33
|
436
|
| Equity in net earnings of subsidiaries |
0
|
0
|
| Accounts and notes receivable |
(6,637)
|
(12,289)
|
| Accrued income taxes |
(8,905)
|
13,922
|
| Other assets |
33,904
|
(41,216)
|
| Accounts payable and accrued liabilities |
(799)
|
47,058
|
| Net cash provided by (used in) operating activities |
32,068
|
36,606
|
| Cash flows from investing activities: |
|
|
| Capital expenditures |
(3,521)
|
(24,418)
|
| Proceeds from the sale of assets |
28
|
50
|
| Proceeds from insurance settlements |
|
0
|
| Net cash (used in) investing activities |
(3,493)
|
(24,368)
|
| Cash flows from financing activities: |
|
|
| Repayments of long-term debt |
|
0
|
| Payment of debt issuance costs |
|
0
|
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability |
(2,000)
|
|
| Excess tax benefit from stock-based compensation |
0
|
0
|
| Intercompany advances, net |
(27,187)
|
(14,840)
|
| Net cash (used in) financing activities |
(29,187)
|
(14,840)
|
| Net increase (decrease) in cash and cash equivalents |
(612)
|
(2,602)
|
| Cash and cash equivalents, beginning of year |
13,854
|
13,546
|
| Cash and cash equivalents, end of period |
13,242
|
10,944
|
| Non-Guarantor [Member] |
|
|
| Cash flows from operating activities: |
|
|
| Net income (loss) |
(1,912)
|
7,225
|
| Adjustments to reconcile net income (loss) |
|
|
| Depreciation and amortization |
12,689
|
17,228
|
| Accretion Expense |
0
|
|
| (Gain) loss on disposition of assets |
4
|
(2,389)
|
| Deferred income tax expense (benefit) |
(549)
|
1,489
|
| Expenses not requiring cash |
(2,199)
|
(1,142)
|
| Equity in net earnings of subsidiaries |
0
|
0
|
| Accounts and notes receivable |
6,256
|
5,620
|
| Accrued income taxes |
(5,375)
|
(581)
|
| Other assets |
2,983
|
(3,887)
|
| Accounts payable and accrued liabilities |
(4,117)
|
17,536
|
| Net cash provided by (used in) operating activities |
8,878
|
38,121
|
| Cash flows from investing activities: |
|
|
| Capital expenditures |
(4,368)
|
(9,037)
|
| Proceeds from the sale of assets |
26
|
196
|
| Proceeds from insurance settlements |
|
2,500
|
| Net cash (used in) investing activities |
(4,342)
|
(6,341)
|
| Cash flows from financing activities: |
|
|
| Repayments of long-term debt |
|
0
|
| Payment of debt issuance costs |
|
0
|
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability |
0
|
|
| Excess tax benefit from stock-based compensation |
0
|
0
|
| Intercompany advances, net |
(1,628)
|
(19,411)
|
| Net cash (used in) financing activities |
(1,628)
|
(19,411)
|
| Net increase (decrease) in cash and cash equivalents |
2,908
|
12,369
|
| Cash and cash equivalents, beginning of year |
46,455
|
58,182
|
| Cash and cash equivalents, end of period |
49,363
|
70,551
|
| Eliminations [Member] |
|
|
| Cash flows from operating activities: |
|
|
| Net income (loss) |
16,225
|
(8,988)
|
| Adjustments to reconcile net income (loss) |
|
|
| Depreciation and amortization |
0
|
0
|
| Accretion Expense |
0
|
|
| (Gain) loss on disposition of assets |
0
|
0
|
| Deferred income tax expense (benefit) |
0
|
0
|
| Expenses not requiring cash |
0
|
0
|
| Equity in net earnings of subsidiaries |
(16,225)
|
8,988
|
| Accounts and notes receivable |
0
|
0
|
| Accrued income taxes |
0
|
0
|
| Other assets |
0
|
0
|
| Accounts payable and accrued liabilities |
0
|
0
|
| Net cash provided by (used in) operating activities |
0
|
0
|
| Cash flows from investing activities: |
|
|
| Capital expenditures |
0
|
0
|
| Proceeds from the sale of assets |
0
|
0
|
| Proceeds from insurance settlements |
|
0
|
| Net cash (used in) investing activities |
0
|
0
|
| Cash flows from financing activities: |
|
|
| Repayments of long-term debt |
|
0
|
| Payment of debt issuance costs |
|
0
|
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability |
0
|
|
| Excess tax benefit from stock-based compensation |
0
|
0
|
| Intercompany advances, net |
0
|
0
|
| Net cash (used in) financing activities |
0
|
0
|
| Net increase (decrease) in cash and cash equivalents |
0
|
0
|
| Cash and cash equivalents, beginning of year |
0
|
0
|
| Cash and cash equivalents, end of period |
$ 0
|
$ 0
|